Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer

NCT01896856 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

118

Enrollment

OTHER

Sponsor class

Conditions

Previously Treated Metastatic Colorectal Cancer

Interventions

DRUG: SGI-110 Dose Escalation
DRUG: Regorafenib
DRUG: TAS-102
DRUG: SGI-110
DRUG: Irinotecan

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]
[object Object]